A saliva-based physiological marker is not necessarily a drug assay. In a small 2013 experiment, methamphetamine increased salivary alpha-amylase activity and that activity correlated with subjective ratings. The finding concerns an enzyme response under controlled conditions, not a validated method for diagnosing methamphetamine exposure or impairment.
What did participants receive?
Haile and colleagues studied eight methamphetamine-dependent volunteers, seven men and one woman, using a double-blind, randomized, placebo-controlled within-person design. Participants received intravenous saline or 30 mg methamphetamine during two sessions on one test day. Samples and ratings were obtained before dosing and at 10, 20, 30, 45 and 60 minutes afterward.
A known administered dose strengthens interpretation of the acute experimental contrast. It does not make the participants representative of first-time users, people taking a different formulation, or drivers assessed outside a controlled laboratory. Route, exposure history and observation period remain part of the result.
What did the saliva assay measure?
The assay measured alpha-amylase enzyme activity. Unstimulated saliva was collected with a swab held under the tongue for 30 seconds. Activity differed significantly between conditions at 20–60 minutes; salivary flow-rate comparisons were not significant.
Enzyme activity and drug concentration are distinct analytes. This experiment did not identify methamphetamine by measuring its chemical structure in saliva. The flow null also matters: the reported activity change should not simply be explained away as an observed reduction in saliva output when the study did not find that reduction.
Where did the number forty come from?
Correlation analyses pooled five post-infusion observations from each of eight participants, producing 40 paired observations. Reported correlations between enzyme activity and several subjective ratings ranged from 0.543 to 0.684.
Forty observations are not forty separately recruited people. Measurements from one participant share that person’s characteristics and can change together over time. Interpreting a pooled association requires distinguishing within-person changes from differences between people; it does not establish a calibrated prediction for a new individual.
Was norepinephrine directly measured?
No norepinephrine measurement was made in this study. The authors explicitly identified that limitation, despite discussing alpha-amylase as a sympathetic-activity biomarker.
A marker’s association with a biological pathway in other literature does not make it a direct measurement of that pathway in every new experiment. This paper can support an observed enzyme response without establishing the precise peripheral or central neurotransmitter concentration responsible for it.
Do subjective ratings establish impairment?
Ratings of feeling a drug effect, stimulation or liking are not themselves performance tests. The paper did not validate a driving-impairment threshold, diagnostic sensitivity or specificity for an enzyme cutoff, or an individual relationship between the enzyme and safe task performance.
The relevant question in a forensic review is therefore which claim is being made. The study measured a physiological response and its association with reported experience. It did not establish a stand-alone toxicology identification test or a substitute for contemporaneous behavioral and analytical evidence.
This historical controlled study is useful precisely when its small participant count, repeated-observation structure, specimen method and measured analyte remain explicit.
Source
Haile CN, De La Garza R II, Mahoney JJ III, Newton TF. Effects of methamphetamine on the noradrenergic activity biomarker salivary alpha-amylase. Drug and Alcohol Dependence. 2013;133(2):759–762. doi:10.1016/j.drugalcdep.2013.07.029. Full text. Small controlled human laboratory study.